Address: At the Rare Hub, 1012 14th Street NW, Suite 500 Washington, DC 20005

Efforts to Cut Drug Prices Would Harm Rare-Disease Patients
Tuesday, February 25, 2020

Source: RealClear Politics   By Michael Eging  Government policy changes sometimes have all the subtlety of a steam roller, barreling forward without sufficient regard for everything in its path. Such is the case today with proposed changes to the Medicare prescription drug benefit (Part D), one of health care’s success stories. In an attempt to…

Read More

Rare Disease Drug Market May be Devastated by Current Proposed Changes to Medicare D, finds the Rare Access Action Project;
Tuesday, February 25, 2020

Study shows Cost Increases for Manufacturers could range from 400 percent to 2,000 percent “Unfortunately, these rather sweeping one-size-fits all plans could actually devastate the orphan drug market that serves patients who already have few options – if any,” said RAAP’s Mike Eging. WASHINGTON D.C. (02-25-2020) – The Rare Access Action Project (RAAP) announced results…

Read More

Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments
Tuesday, February 25, 2020

With almost 50 million beneficiaries enrolled in the program, the Medicare prescription drug benefit (Part D) is considered by many to be a model of a successful government insurance program. Beneficiary premiums have declined 13.5% over the past 5 years, and most regions of the country have many prescription drug plan options for beneficiaries. Despite…

Read More

Medicare Part D
Thursday, October 31, 2019

Source: Washington Times A sledgehammer on a fragile market, when a scalpel is needed Making Changes to Medicare Part D that protect those with Rare Diseases By Michael Eging – Thursday, October 31, 2019   When is the last time anyone heard of a government program not only working well, but also coming in under…

Read More